The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for corneal cystine crystal accumulation in patients with cystinosis.
Kodiak Sciences reports positive topline results from BEACON Phase 3 study of tarcocimab in patients with retinal vein occlusion
Inflammatory bowel disease does not have ocular manifestations
Innovent announces first patient dosed in Phase 1 study of IBI324 in patients with diabetic macular edema
